Publications
- Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.Wang R, Shallis RM, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Blood Adv. 2023 Mar 14. PMID: 35917456.
- Is it the time to integrate novel sequencing technologies into clinical practice?VanOudenhove J, Halene S, Mendez L. Curr Opin Hematol. 2023 Mar 1; 2022 Dec 30. PMID: 36602939.
- Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia.Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Podoltsev NA, Stahl M, Stein EM, Huntington SF, Zeidan AM. Leuk Lymphoma. 2023 Feb; 2022 Dec 9. PMID: 36493798.
- Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes.Fischer MA, Song Y, Arrate MP, Gbyli R, Villaume MT, Smith BN, Childress MA, Stricker TP, Halene S, Savona MR. Haematologica. 2023 Feb 1; 2023 Feb 1. PMID: 35979721.
- Deconvolution of in vivo protein-RNA contacts using fractionated eCLIP-seq.Biancon G, Busarello E, Joshi P, Lesch BJ, Halene S, Tebaldi T. STAR Protoc. 2022 Dec 16; 2022 Nov 16. PMID: 36595959.
- Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts.Adema V, Ma F, Kanagal-Shamanna R, Thongon N, Montalban-Bravo G, Yang H, Peslak SA, Wang F, Acha P, Sole F, Lockyer P, Cassari M, Maciejewski JP, Visconte V, Gañán-Gómez I, Song Y, Bueso-Ramos C, Pellegrini M, Tan TM, Bejar R, Carew JS, Halene S, Santini V, Al-Atrash G, Clise-Dwyer K, Garcia-Manero G, Blobel GA, Colla S. Blood Cancer Discov. 2022 Nov 2. PMID: 35926182.
- The case for classical haematology: the impact of a name and the future of a field.Al-Samkari H, Loren AW, Lee AI. Lancet Haematol. 2022 Jun; 2022 Apr 29. PMID: 35500590.
- Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?Shallis RM, Bewersdorf JP, Stahl MF, Halene S, Zeidan AM. Cancers (Basel). 2022 May 14; 2022 May 14. PMID: 35626039.
- In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, Flavell RA, Prebet T, Bindra RS, Halene S. Leukemia. 2022 May; 2022 Mar 10. PMID: 35273342.
- The Coming of Age of Preclinical Models of MDS.Liu W, Teodorescu P, Halene S, Ghiaur G. Front Oncol. 2022; 2022 Mar 16. PMID: 35372085.
- Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States.Shallis RM, Wang R, Bewersdorf JP, Zeidan AM, Davidoff AJ, Huntington SF, Podoltsev NA, Ma X. Ther Adv Hematol. 2021; 2021 Nov 30. PMID: 35154624.
- Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia.Bewersdorf JP, Patel KK, Huntington SF, Zeidan AM. Blood Adv. 2021 Nov 23. PMID: 34525174.
- Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.Patel KK, Parker T, Di M, Bar N, Huntington SF, Giri S. Leuk Lymphoma. 2021 Nov; 2021 Jun 21. PMID: 34151696.
- Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinase.Boddu PC, Gupta AK, Kim JS, Neugebauer KM, Waldman T, Pillai MM. Commun Biol. 2021 Oct 13; 2021 Oct 13. PMID: 34645977.
- Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases.Bewersdorf JP, Parmar N, Israel GM, Gettinger SN, Lee AI. J Thromb Thrombolysis. 2021 Oct; 2021 Mar 25. PMID: 33765243.
- Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases.Li P, Biancon G, Patel T, Pan Z, Kothari S, Halene S, Prebet T, Xu ML. Front Oncol. 2021; 2021 Sep 13. PMID: 34589432.